Brought to you by:
Three honored in VAM 2025 Poster Competition
The final day of the 2025 Vascular Annual Meeting (VAM) in New Orleans honored three winners in the championship round of the SVS Poster Competition. The audience voted to select the winners from more than 100 entries highlighting innovative research.…
ATEV shows promise in high-risk patients on hemodialysis
Results from the CLN-PRO-V007 pivotal phase 3 clinical trial of the acellular tissue engineered vessel (ATEV; Humacyte) in arteriovenous access for patients at high risk of autologous arteriovenous fistula (AVF) maturation failure with end-stage renal disease were presented at the…
Acellular tissue engineered vessel outperforms AVF in high-risk hemodialysis patients
Results from the CLN-PRO-V007 randomized controlled trial of Humacyte’s acellular tissue engineered vessel (ATEV) are set to be shared today during VAM 2025 Plenary 6 (10–11 a.m., First Floor, Great Hall A), showing several clinical benefits when compared to arteriovenous…
TCAR and endarterectomy both ‘reasonable’ but stenting linked to worse outcomes in kidney disease patients
A study examining outcomes between different carotid revascularisation procedures has concluded that transcarotid artery revascularisation (TCAR) and carotid endarterectomy (CEA) both represent a “reasonable choice” in severe chronic kidney disease (CKD) and haemodialysis patients—but transfemoral carotid artery stenting (TF-CAS) appears more likely to result…
TCAR and endarterectomy both ‘reasonable’ but stenting linked to worse outcomes in kidney disease patients
A study examining outcomes between different carotid revascularization procedures has concluded that transcarotid artery revascularization (TCAR) and carotid endarterectomy (CEA) both represent a “reasonable choice” in severe chronic kidney disease (CKD) and hemodialysis patients—but transfemoral carotid artery stenting (TF-CAS) appears…
VasQ: The next standard-of-care innovation
This advertorial is sponsored by Laminate Medical Technologies. At the 2024 Charing Cross (CX) International Symposium (April 23–25) in London, England, the Vascular Access Masterclass Controversies session delved into the question, “We have new technology, but do we need it?”…
The utility of renal stenting in hemodialysis patients: One in five found to come off dialysis after being stented
A fifth of patients among a chronic kidney disease (CKD) cohort on hemodialysis—a rare subset pulled from a large repository of national data—were able to come off the treatment following renal artery stenting, a team of researchers from the University…
EVS 2023: New data chart underrepresentation of women at the head of national clinical trials
The underrepresentation of women vascular surgeons in national clinical trial leadership formed the central theme of data coming out of a new study that probed all clinical trials in five main areas of vascular disease between 1997 and 2003. Delivered…
VasQ AVF creation device receives FDA clearance
Laminate Medical Technologies has announced their flagship device, the VasQ external vascular support, has been cleared by the Food and Drug Administration (FDA) for use to create arteriovenous fistulas (AVFs) for dialysis access. The device, designated by the FDA as…
Nephrologist insights for vascular surgeons at hemodialysis access session
Friday afternoon in Potomac D will see VAM play host to a series of presentations on access for hemodialysis that will offer education on arteriovenous fistulas (AVFs), grafts (AVGs) and maturation—as well as strategies for managing their failure. The session…